Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Syphilis: Prevention and Risk Reduction: Barrier Protection, Doxy-PEP, Routine and Prenatal Screening, and Partner Treatment

A preventive medicine reference on barrier protection including oral sex, doxycycline post-exposure prophylaxis, routine and prenatal serologic screening, and presumptive treatment of exposed partners.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • This is an accurate and current brief. The doxy-PEP section is well specified, including the dosing window, eligibility and the practical administration advice that most sources omit. The prenatal screening schedule and the presumptive partner treatment windows are correct. The notes below are additions.
  • The window period is missing, and it undercuts the pre-intimacy testing advice. Syphilis serology can take up to about three months after exposure to become reliably positive. A partner who tested negative last week is only cleared of exposures from more than three months ago, and a negative test soon after a possible exposure needs repeating.
  • Doxy-PEP did not show the same benefit in cisgender women in the trial that tested it, with adherence offered as one explanation. The brief correctly describes the recommended populations and should say this explicitly, because women reading the efficacy figures will reasonably assume they apply.
  • Doxy-PEP is not used in pregnancy. Given that the same document covers prenatal prevention, the two sections should be connected.
  • Congenital syphilis deserves more than a prevention mechanism. Rates have risen sharply in the United States over the past decade, and reviews of cases consistently find the same causes: no prenatal care, late prenatal care, testing not repeated, or a positive result not acted on quickly. The failures are almost never clinically complex. Stating that makes the screening schedule feel less like a formality.
  • Neurological, ocular and otic syphilis can occur at any stage, including within weeks of infection. The brief refers to severe neurological complications in a way that implies they are late events. Ocular syphilis in particular has become more common alongside rising incidence, and new vision or hearing symptoms at any stage are urgent.
  • Syphilis increases both the risk of acquiring HIV and the risk of transmitting it, through mucosal ulceration. That is a direct argument for the screening intervals the brief recommends and for pairing a syphilis diagnosis with HIV testing and PrEP discussion.
  • Reinfection after treatment deserves a line in a prevention document. Cure gives no immunity, reinfection is common where exposure continues, and continued screening after successful treatment is the practical consequence.
  • One practical addition to the screening section: syphilis is a blood test and is not always included in a routine STI screen, which is often urine and swab based. It frequently has to be requested by name.
  • Everything else in the brief is accurate: Treponema pallidum and transmission through contact with chancres and secondary mucocutaneous lesions during vaginal, anal and oral sex and vertically in pregnancy; painless chancres going unnoticed in the vagina, rectum and mouth; the absence of a licensed vaccine and of immunity after cure; condom use with the correct caveat that sores on uncovered skin still transmit; barriers for oral sex; avoiding contact with any unexplained sore or rash until assessed; the doxy-PEP dose, timing window, efficacy range, eligibility criteria and administration advice including upright dosing and photosensitivity; the screening intervals; the prenatal schedule at first visit, 28 weeks and delivery; and presumptive treatment of partners exposed within 90 days with longer lookback windows for later stages.

Download the PDF

All source documents